Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–68 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Osteoarthritis of the Knee Clear all
Terminated Phase 3 Interventional Results available

Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

NCT03349645
View directory record Official record
Conditions
Severe Osteoarthritis of the Knee
Interventions
4 mL injection of AMPION™
Biological
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Encinitas, California • Fullerton, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects

NCT01733186
View directory record Official record
Conditions
Degeneration Articular Cartilage Knee
Interventions
CARTISTEM®
Biological
Lead sponsor
Medipost, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

NCT03182686
View directory record Official record
Conditions
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic
Interventions
4 mL injection of Ampion, 4 mL Injection of Placebo
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
13
States / cities
Birmingham, Alabama • Encinitas, California • Fullerton, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 1 Interventional

To Assess the Patients' Ability to Self-Administer Fasinumab

NCT03491904
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab AI, Fasinumab PFS
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
Gilbert, Arizona • Glendale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 2 Interventional

Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain

NCT02104050
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo Gel, OLT1177 Gel
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Birmingham, Alabama • Milford, Connecticut • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 9, 2026, 10:28 PM EDT
Terminated Phase 3 Interventional Results available

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

NCT03988023
View directory record Official record
Conditions
Severe Osteoarthritis of the Knee
Interventions
Ampion, Saline
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

NCT04385303
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Lorecivivint, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee

NCT01887678
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Traumeel® / Zeel® Injectable Solution, Placebo
Drug
Lead sponsor
Biologische Heilmittel Heel GmbH
Industry
Eligibility
45 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Dinuba, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 9, 2026, 10:28 PM EDT
Completed No phase listed Observational

An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

NCT02951026
View directory record Official record
Conditions
Osteoarthritis
Interventions
Not applicable (no therapy is administered as part of this study)
Other
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
62
States / cities
Birmingham, Alabama • Oro Valley, Arizona • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 2 Interventional

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

NCT00394563
View directory record Official record
Conditions
Osteoarthritis
Interventions
RN624 (PF-04383119), placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2009 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

NCT03660943
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Placebo, CNTX-4975-05
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Glendale, Arizona • Phoenix, Arizona • Carmichael, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Not applicable Interventional

Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee

NCT00928837
View directory record Official record
Conditions
Osteoarthritis
Interventions
Flavocoxid 500 mg, Naproxen, Placebo, flavocoxid 250 mg
Dietary Supplement · Drug · Other
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
35 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 9, 2026, 10:28 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

NCT04885972
View directory record Official record
Conditions
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
Interventions
Resiniferatoxin, Zilretta, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
La Mesa, California • Pasadena, California • Oak Brook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

NCT01221441
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
TissueGene-C, Normal Saline
Biological · Drug
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Pinellas Park, Florida • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

NCT03028870
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
V120083, Naproxen, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
30
States / cities
Birmingham, Alabama • Tuscumbia, Alabama • North Hollywood, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 9, 2026, 10:28 PM EDT
Terminated Phase 3 Interventional Results available

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

NCT03285646
View directory record Official record
Conditions
Chronic Low Back Pain, Osteoarthritis
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee

NCT00371670
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
balicatib (AAE581)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
223 participants
Timeline
Started 2004
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 9, 2026, 10:28 PM EDT
Active, not recruiting Phase 2 Interventional

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

NCT06865079
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
TPX-100 200mg, Once weekly for 4 weeks, PBS
Drug · Other
Lead sponsor
OrthoTrophix, Inc
Industry
Eligibility
50 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Scottsdale, Arizona • Tucson, Arizona • Carrolton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 9, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

NCT05377489
View directory record Official record
Conditions
Osteoarthritis
Interventions
RTX-GRT7039
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
27
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 9, 2026, 10:28 PM EDT